Literature DB >> 1253102

The metabolism of cyclophosphamide. Dose dependency and the effect of long-term treatment with cyclophosphamide.

H T Mouridsen, O Faber, L Skovsted.   

Abstract

Studies on the metabolism of cyclophosphamide-14C were performed in 10 subjects at different single dose levels within the range of 0.02-10 mg/kg body-weight and in five subjects before and following an average 22 days treatment with cyclophosphamide in daily doses of 2 mg/kg. The parameters of cyclophosphamide metabolism--serum half-life of unchanged cyclophosphamide, serum concentration of metabolites, and rates of excretion of cyclophosphamide and metabolites in the urine--were all independent of dose. No change of the metabolism was demonstrated after treatment with cyclophosphamide for 22 days.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1253102     DOI: 10.1002/1097-0142(197602)37:2<665::aid-cncr2820370209>3.0.co;2-d

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  13 in total

1.  The pharmacokinetics of ifosfamide given as short and long intravenous infusions in cancer patients.

Authors:  L D Lewis; D L Fitzgerald; P Mohan; N Thatcher; P G Harper; H J Rogers
Journal:  Br J Clin Pharmacol       Date:  1991-01       Impact factor: 4.335

Review 2.  Pharmacokinetic drug interactions of commonly used anticancer drugs.

Authors:  F M Balis
Journal:  Clin Pharmacokinet       Date:  1986 May-Jun       Impact factor: 6.447

Review 3.  Clinical pharmacokinetics of cyclophosphamide.

Authors:  L B Grochow; M Colvin
Journal:  Clin Pharmacokinet       Date:  1979 Sep-Oct       Impact factor: 6.447

4.  Repeated high-dose cyclophosphamide administration in bone marrow transplantation: exposure to activated metabolites.

Authors:  U Schuler; G Ehninger; T Wagner
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

5.  The pharmacokinetics of cyclophosphamide, phosphoramide mustard and nor-nitrogen mustard studied by gas chromatography in patients receiving cyclophosphamide therapy.

Authors:  F D Juma; H J Rogers; J R Trounce
Journal:  Br J Clin Pharmacol       Date:  1980-10       Impact factor: 4.335

6.  Pharmacokinetics of cyclophosphamide and alkylating activity in man after intravenous and oral administration.

Authors:  F D Juma; H J Rogers; J R Trounce
Journal:  Br J Clin Pharmacol       Date:  1979-09       Impact factor: 4.335

7.  Pharmacokinetics of high-dose cyclophosphamide in patients with metastatic bronchogenic carcinoma.

Authors:  P M Wilkinson; P A O'Neill; N Thatcher; S B Lucas
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

Review 8.  Ifosfamide pharmacokinetics.

Authors:  L D Lewis
Journal:  Invest New Drugs       Date:  1991-11       Impact factor: 3.850

Review 9.  Clinical pharmacokinetics of commonly used anticancer drugs.

Authors:  F M Balis; J S Holcenberg; W A Bleyer
Journal:  Clin Pharmacokinet       Date:  1983 May-Jun       Impact factor: 6.447

Review 10.  Proposal for the assessment of quantitative dermal exposure limits in occupational environments: Part 1. Development of a concept to derive a quantitative dermal occupational exposure limit.

Authors:  P M Bos; D H Brouwer; H Stevenson; P J Boogaard; W L de Kort; J J van Hemmen
Journal:  Occup Environ Med       Date:  1998-12       Impact factor: 4.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.